Abstract
Cancer cells are able to escape surveillance from the immune system by co-opting physiologic mechanisms such as the programmed cell death-1 (PD-1) receptor pathway. Agents able to block the interaction between the PD-1 receptor and its ligands have the potential to release T cells from tumor-induced suppression and eradicate malignant cells. Nivolumab-a PD-1 inhibitor-is approved for the treatment of patients with metastatic melanoma and lung cancer. This agent has been tested in patients with advanced Hodgkin lymphoma (HL) and showed impressive results in a phase I trial. Here we review the profile of Nivolumab including its pharmacological properties, clinical efficacy and safety in patients with advanced classical HL.
Original language | English (US) |
---|---|
Pages (from-to) | 5-12 |
Number of pages | 8 |
Journal | Expert Review of Anticancer Therapy |
Volume | 16 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2 2016 |
Keywords
- checkpoint inhibitors
- Hodgkin lymphoma
- immunerelated adverse events
- Immunotherapy
- nivolumab
- PD-1
- PD-L1
ASJC Scopus subject areas
- Pharmacology (medical)
- Oncology